The experience with Bendectin (doxylamine succinate and pyridoxine hydrochloride, for treating nausea and vomiting of pregnancy) reveals how non–science-based decisions may affect the availability of a drug product, with adverse public health consequences.
No takes yet. Share an insight, caveat, or question.
Slaughter et al. (2014) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: